09:58 AM EST, 03/08/2024 (MT Newswires) -- Insulet ( PODD ) said Friday that trial data showed "improved glycemic and patient-reported outcomes" in type 1 diabetes with the use of the company's Omnipod 5 insulin delivery system compared with insulin pump therapy.

"Omnipod 5 use led to a 17.5% improvement in time in range, decreased HbA1c, decreased percentage of time in hypoglycemia, and decreased mean glucose in individuals with baseline HbA1c levels above the recommended target," the company said.

The study results were presented at the International Conference on Advanced Technologies & Treatments for Diabetes in Italy, Insulet ( PODD ) said.

Insulet ( PODD ) shares were nearly 2% higher in recent trading.

Price: 178.74, Change: +3.25, Percent Change: +1.85